A
AOBiome
NitroCell BioSciences LLC was incorporated in 2012 and is based in Newton, Massachusetts
About AOBiome
AOBiome Therapeutics is a clinical-stage life sciences company focused on developing innovative therapies that harness the power of Ammonia Oxidizing Bacteria (AOB) to address chronic inflammatory conditions. The company operates in the biopharmaceutical market, targeting conditions such as hypertension, acne, allergic rhinitis, migraine, eczema, and rosacea. AOBiome's proprietary product candidates utilize a single strain of AOB, a naturally occurring microorganism with well-characterized biochemical properties essential to human health. These candidates aim to restore the symbiotic relationship between bacteria and humans, which has been disrupted by modern lifestyle factors such as the use of surfactants and antibiotics. AOBiome's business model involves advancing its product candidates through clinical trials, with the goal of obtaining regulatory approval and commercializing these therapies. The company generates revenue through partnerships, licensing agreements, and eventually, product sales. To date, AOBiome has completed six Phase 2 clinical programs and multiple preclinical programs, enrolling over 1,000 patients since 2016.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Cambridge, United States
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 77.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Synthetic Biology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | Jan 2017 | $30M | $120M | iCarbonX | — |
| SERIES B✓Equity / VC | Dec 2014 | $7.5M | $30M | Hedgewood | — |
Growth signals
Latest recorded traffic for AOBiome is 2.6K monthly website visits, up 100% over the last three months. AOBiome's team grew 12.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Hedgewood
Series B and later1 investor entered at this stage
iCarbonX
Other known investors2 additional known investors
MBC Biolabs
Wild Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AOBiome on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AOBiome’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.